 | • レポートコード：MRC22iR11008 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品 |
| Single User | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Five User | ￥880,452 (USD5,949) | ▷ お問い合わせ |
| Enterprise License | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に9,614.04 百万ドルであった世界の経因性疼痛治療薬市場規模が、2022年に10,526.47百万ドルになり、2027年まで年平均9.66%で成長して16,725.38百万ドルに達すると予測しています。本レポートでは、経因性疼痛治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場洞察、種類別（幻肢痛、帯状疱疹後神経痛、外傷後神経障害、三叉神経痛）分析、治療法別（抗うつ剤、薬物療法）分析、疾患別（糖尿病性神経障害、脊柱管狭窄症）分析、診断別（血液検査、画像診断、CT、筋電図、MRI）分析、地域別（南北アメリカ、アジア太平洋、ヨーロッパ）分析、競争状況、企業情報などの項目を掲載しています。本書ではAbbott、Allergan, Inc.、Astellas、AstraZeneca、Bausch Health Companies Inc.、Baxter Healthcare Corporation、Biogen Idec Inc.、Bristol-Myers Squibb and Company、Cara Therapeutics、CODA Biotherapeutics, Inc.、Collegium Pharmaceuticals、Depomed、Depomed Inc.、Eli Lily and Company、Endo International plcなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場洞察 ・世界の経因性疼痛治療薬市場規模：種類別 - 幻肢痛治療薬の市場規模 - 帯状疱疹後神経痛治療薬の市場規模 - 外傷後神経障害治療薬の市場規模 - 三叉神経痛治療薬の市場規模 ・世界の経因性疼痛治療薬市場規模：治療法別 - 抗うつ剤療法の市場規模 - 薬物療法の市場規模 ・世界の経因性疼痛治療薬市場規模：疾患別 - 糖尿病性神経障害における市場規模 - 脊柱管狭窄症における市場規模 ・世界の経因性疼痛治療薬市場規模：診断別 - 血液検査の市場規模 - 画像診断の市場規模 - CT診断の市場規模 - 筋電図診断の市場規模 - MRI診断の市場規模 ・世界の経因性疼痛治療薬市場規模：地域別 - 南北アメリカの経因性疼痛治療薬市場規模 - アジア太平洋の経因性疼痛治療薬市場規模 - ヨーロッパの経因性疼痛治療薬市場規模 ・競争状況 ・企業情報 |
The Global Neuropathic Pain Drug Market size was estimated at USD 9,614.04 million in 2021 and expected to reach USD 10,526.47 million in 2022, and is projected to grow at a CAGR 9.66% to reach USD 16,725.38 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Neuropathic Pain Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.
Based on Treatment, the market was studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
Based on Indication, the market was studied across Diabetic Neuropathy and Spinal Stenosis.
Based on Diagnosis, the market was studied across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination is further studied across CT, Electromyography, and MRI.
Based on Distribution, the market was studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
Based on End User, the market was studied across Clinics and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neuropathic Pain Drug market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathic Pain Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuropathic Pain Drug Market, including Abbott, Allergan, Inc., Astellas, AstraZeneca, Bausch Health Companies Inc., Baxter Healthcare Corporation, Biogen Idec Inc., Bristol-Myers Squibb and Company, Cara Therapeutics, CODA Biotherapeutics, Inc., Collegium Pharmaceuticals, Depomed, Depomed Inc., Eli Lily and Company, Endo International plc, GlaxoSmithKline PLC, Grünenthal, GSK, Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Neuroheal Biomedicals, Novartis International AG, Pacira BioSciences, Pfizer Inc., Purdue Pharma L.P., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Neuropathic Pain Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuropathic Pain Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuropathic Pain Drug Market?
4. What is the competitive strategic window for opportunities in the Global Neuropathic Pain Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Neuropathic Pain Drug Market?
6. What is the market share of the leading vendors in the Global Neuropathic Pain Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Neuropathic Pain Drug Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of chronic diseases such as diabetes and cancer globally
5.1.1.2. Rising advancement of healthcare systems across the world
5.1.1.3. Availability of numerous approved drugs at retail pharmacies
5.1.2. Restraints
5.1.2.1. Probable side effects that could lead to death
5.1.3. Opportunities
5.1.3.1. Surge in awareness related to neuropathic pain in emerging economies
5.1.3.2. Ongoing technological innovations and development of drugs
5.1.4. Challenges
5.1.4.1. Concerns over incomplete pain relief
5.2. Cumulative Impact of COVID-19
6. Neuropathic Pain Drug Market, by Type
6.1. Introduction
6.2. Phantom Limb Pain
6.3. Post Herpetic Neuralgia
6.4. Post-traumatic Neuropathy
6.5. Trigeminal Neuralgia
7. Neuropathic Pain Drug Market, by Treatment
7.1. Introduction
7.2. Antidepressant Drugs Type
7.3.1. Serotonin Noradrenaline
7.3.2. Tricyclic Antidepressants
7.3. Medication Type
7.4. Multimodal Therapy
7.5. NSAIDs Type
7.6.1. Ibuprofen
7.6.2. Naproxen
8. Neuropathic Pain Drug Market, by Indication
8.1. Introduction
8.2. Diabetic Neuropathy
8.3. Spinal Stenosis
9. Neuropathic Pain Drug Market, by Diagnosis
9.1. Introduction
9.2. Blood Tests
9.3. Imaging Physical Examination
9.4.1. CT
9.4.2. Electromyography
9.4.3. MRI
10. Neuropathic Pain Drug Market, by Distribution
10.1. Introduction
10.2. Online Pharmacies
10.3. Retail Pharmacies & Drug Stores
11. Neuropathic Pain Drug Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
12. Americas Neuropathic Pain Drug Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Neuropathic Pain Drug Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Neuropathic Pain Drug Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbott
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Allergan, Inc.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Astellas
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. AstraZeneca
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Bausch Health Companies Inc.
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Baxter Healthcare Corporation
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Biogen Idec Inc.
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Bristol-Myers Squibb and Company
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. Cara Therapeutics
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. CODA Biotherapeutics, Inc.
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. Collegium Pharmaceuticals
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. Depomed
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. Depomed Inc.
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Eli Lily and Company
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Endo International plc
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. GlaxoSmithKline PLC
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Grünenthal
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. GSK
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
16.19. Johnson & Johnson Services Inc.
16.19.1. Business Overview
16.19.2. Key Executives
16.19.3. Product & Services
16.20. Mallinckrodt Pharmaceuticals
16.20.1. Business Overview
16.20.2. Key Executives
16.20.3. Product & Services
16.21. Neuroheal Biomedicals
16.21.1. Business Overview
16.21.2. Key Executives
16.21.3. Product & Services
16.22. Novartis International AG
16.22.1. Business Overview
16.22.2. Key Executives
16.22.3. Product & Services
16.23. Pacira BioSciences
16.23.1. Business Overview
16.23.2. Key Executives
16.23.3. Product & Services
16.24. Pfizer Inc.
16.24.1. Business Overview
16.24.2. Key Executives
16.24.3. Product & Services
16.25. Purdue Pharma L.P.
16.25.1. Business Overview
16.25.2. Key Executives
16.25.3. Product & Services
16.26. Sanofi S.A.
16.26.1. Business Overview
16.26.2. Key Executives
16.26.3. Product & Services
16.27. Teva Pharmaceutical Industries Ltd
16.27.1. Business Overview
16.27.2. Key Executives
16.27.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing